Effect of C1‐Esterase‐inhibitor in angiotensin‐converting enzyme inhibitor‐induced angioedema. (13th January 2015)
- Record Type:
- Journal Article
- Title:
- Effect of C1‐Esterase‐inhibitor in angiotensin‐converting enzyme inhibitor‐induced angioedema. (13th January 2015)
- Main Title:
- Effect of C1‐Esterase‐inhibitor in angiotensin‐converting enzyme inhibitor‐induced angioedema
- Authors:
- Greve, Jens
Bas, Murat
Hoffmann, Thomas K.
Schuler, Patrick J.
Weller, Patrick
Kojda, Georg
Strassen, Ulrich - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="lary25113-sec-0001" sec-type="section"> <title>Objectives/Hypothesis</title> <p>The study objective was to generate pilot data to evaluate the effectiveness and safety of C1‐esterase‐inhibitor concentrate (C1‐INH) compared to standard treatment in patients with angiotensin‐converting enzyme inhibitor (ACEi)‐induced angioedema affecting the upper aerodigestive tract.</p> </sec> <sec id="lary25113-sec-0002" sec-type="section"> <title>Study Design</title> <p>Proof‐of‐concept case series with historical control.</p> </sec> <sec id="lary25113-sec-0003" sec-type="section"> <title>Methods</title> <p>Adult patients with angioedema in the upper aerodigestive tract presenting to the emergency department were included. After establishing the diagnosis of ACEi‐induced angioedema based on patient history and thorough clinical examination, all patients were administered 1, 000 international units (IU) of C1‐INH intravenously. A historical control group consisting of adult patients with ACEi‐induced angioedema who had been treated with intravenous corticosteroids and antihistamines at the same institution over the past 8 years was used for comparison. The most important parameters assessed were the time to complete resolution of symptoms and the need for intubation or tracheotomy.</p> </sec> <sec id="lary25113-sec-0004" sec-type="section"> <title>Results</title> <p>Ten patients were included in<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="lary25113-sec-0001" sec-type="section"> <title>Objectives/Hypothesis</title> <p>The study objective was to generate pilot data to evaluate the effectiveness and safety of C1‐esterase‐inhibitor concentrate (C1‐INH) compared to standard treatment in patients with angiotensin‐converting enzyme inhibitor (ACEi)‐induced angioedema affecting the upper aerodigestive tract.</p> </sec> <sec id="lary25113-sec-0002" sec-type="section"> <title>Study Design</title> <p>Proof‐of‐concept case series with historical control.</p> </sec> <sec id="lary25113-sec-0003" sec-type="section"> <title>Methods</title> <p>Adult patients with angioedema in the upper aerodigestive tract presenting to the emergency department were included. After establishing the diagnosis of ACEi‐induced angioedema based on patient history and thorough clinical examination, all patients were administered 1, 000 international units (IU) of C1‐INH intravenously. A historical control group consisting of adult patients with ACEi‐induced angioedema who had been treated with intravenous corticosteroids and antihistamines at the same institution over the past 8 years was used for comparison. The most important parameters assessed were the time to complete resolution of symptoms and the need for intubation or tracheotomy.</p> </sec> <sec id="lary25113-sec-0004" sec-type="section"> <title>Results</title> <p>Ten patients were included in the C1‐INH group and 47 in the corticosteroid/antihistamine group. The time to complete resolution of symptoms was considerably longer in the historical control group (33.1 ± 19.4 hours) than in the C1‐INH group (10.1 ± 3.0 hours). No intubation or tracheotomy was needed in the C1‐INH group (0/10 patients), whereas three out of the 47 historical controls required tracheotomy and two were intubated (5/47).</p> </sec> <sec id="lary25113-sec-0005" sec-type="section"> <title>Conclusion</title> <p>The results suggest a role for C1‐INH as an effective and safe therapeutic option in patients with ACEi‐induced angioedema, which needs to be confirmed by further larger and double‐blinded studies.</p> </sec> <sec id="lary25113-sec-0006" sec-type="section"> <title>Level of Evidence</title> <p>4. <italic>Laryngoscope</italic>, 125:E198–E202, 2015</p> </sec> </abstract> … (more)
- Is Part Of:
- Laryngoscope. Volume 125:Number 6(2015:Jun.)
- Journal:
- Laryngoscope
- Issue:
- Volume 125:Number 6(2015:Jun.)
- Issue Display:
- Volume 125, Issue 6 (2015)
- Year:
- 2015
- Volume:
- 125
- Issue:
- 6
- Issue Sort Value:
- 2015-0125-0006-0000
- Page Start:
- E198
- Page End:
- E202
- Publication Date:
- 2015-01-13
- Subjects:
- Otolaryngology -- Periodicals
617.51005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1531-4995/issues ↗
http://www.interscience.wiley.com/jpages/0023-852X ↗
http://www.laryngoscope.com ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/lary.25113 ↗
- Languages:
- English
- ISSNs:
- 0023-852X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5156.200000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4096.xml